ACTC1 Gene – Familial Hypertrophic Cardiomyopathy Type 11 (Genetic Test) in UAE | 2800 AED

Executive Summary & Core Metrics

This Next-Generation Sequencing (NGS) test offers 99.9% diagnostic sensitivity for detecting pathogenic variants in the ACTC1 gene associated with Familial Hypertrophic Cardiomyopathy (HCM) Type 11. Performed at our ISO 9001:2015 accredited laboratory, results are available within 21–28 days. The test supports definitive molecular diagnosis, cascade screening for at-risk family members, and pre-conception risk assessment. Direct billing verification is available via WhatsApp: +971 54 548 8731.

Test Overview & Methodology

The ACTC1 gene encodes cardiac alpha-actin, a key sarcomeric protein. Pathogenic variants cause Familial Hypertrophic Cardiomyopathy Type 11, an autosomal dominant disorder characterised by left ventricular hypertrophy, diastolic dysfunction, and increased risk of sudden cardiac arrest. Our test uses NGS to sequence the entire coding region and splice junctions of ACTC1 with mean coverage depth >200x. Variant interpretation follows ACMG/AMP guidelines, with all pathogenic and likely pathogenic variants confirmed by Sanger sequencing.

Feature	Our ACTC1 NGS Test	Closest Alternative (Single-Gene PCR)
Precision	99.9% diagnostic sensitivity via full gene coverage and ISO-accredited NGS	Limited to known hotspot mutations; higher false-negative risk
Methodology	Next-Generation Sequencing (ISO 9001:2015 certified)	Sanger sequencing or targeted PCR
Turnaround Time	3–4 Weeks (comprehensive analysis with expert interpretation)	6–8 weeks (fragmented, manual workflows)

Physician Insight & Safety Protocols

“Genetic testing for ACTC1 provides critical diagnostic clarity, but results must always be correlated with clinical findings, family history, and echocardiographic data. A negative test does not eliminate hereditary risk, especially in families with a strong phenotypic presentation. Pre- and post-test genetic counselling ensure informed decision-making and appropriate medical follow-up.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Safety Advisory

Do not discontinue prescribed medication, including beta-blockers or anticoagulants, without consulting your physician. Genetic testing does not replace emergency care for acute symptoms.

Exclusion Criteria & Pre-test Requirements

Pre-test genetic counselling with a qualified genetic counsellor is mandatory; patients who cannot attend a counselling session may not qualify for insurance coverage.
Blood draw is contraindicated in the presence of severe coagulopathy, active infection at the venipuncture site, or known bleeding disorders.
Emergency Red Flags: Sudden cardiac arrest, unexplained syncope, or severe chest pain require immediate emergency care—do not wait for test results.

Patient FAQ & Clinical Guidance

1. What is the accuracy of this test for detecting ACTC1 mutations?

This NGS-based test delivers 99.9% analytical sensitivity for all coding regions and splice junctions of ACTC1, ensuring no common pathogenic variant is missed. All reportable variants are confirmed by orthogonal Sanger sequencing.

2. How long does it take to receive results and what support is provided?

Results are available within 3 to 4 weeks from sample collection. A post‑test telephonic clinical guidance session with a genetic specialist is provided to interpret findings and discuss implications for you and your family.

3. Is this test covered by UAE health insurance?

Direct billing verification is available via WhatsApp at +971 54 548 8731. Many UAE insurance policies cover genetic testing for cardiomyopathy when medically indicated and pre-authorised. Our team assists with the approval process.

4. Do I need genetic counselling before the test?

Yes, a mandatory pre-test genetic counselling session is required to document family history, discuss inheritance patterns, and obtain informed consent. Our genetic counsellor will contact you to schedule this appointment.

5. What sample type is required, and how is it collected?

A standard peripheral whole blood sample (4 mL in EDTA tube) is required. Our VIP Mobile Phlebotomy service offers temperature-controlled home collection daily from 8 AM to 11 PM. Alternatively, you may visit our Dubai Healthcare City collection centre.

UAE Regulatory & Data Privacy Adherence

Our genetic testing services comply with the following UAE legal frameworks:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Ensures secure handling, storage, and processing of your genetic and health data, with explicit consent requirements and the right to access, rectify, or delete your data.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Governs the use of digital health technologies, telemedicine, and electronic health records to maintain confidentiality and integrity of patient information.
Federal Decree-Law No. 4 of 2016 on Medical Liability: Defines the legal responsibilities of healthcare providers regarding patient safety, informed consent, and clinical governance.

Our laboratory is DHA-licensed (Facility No. 1143) and holds ISO 9001:2015 certification (INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	ACTC1 Gene – Familial Hypertrophic Cardiomyopathy Type 11 (Genetic Test)
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks (21–28 calendar days from sample receipt)
Sample Type / Matrix	Peripheral whole blood (4 mL EDTA tube); VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM)
Methodology Used	Next-Generation Sequencing (NGS) – Full gene coding exons and splice junctions; variant confirmation by Sanger sequencing
ICD-10-CM Code	I42.1 (Hypertrophic obstructive cardiomyopathy), Z13.71 (Encounter for genetic testing for cardiovascular disease)
LOINC Code	92934-7 (ACTC1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method)
DHA Facility License & Laboratory Address	DHA License No. 1143 \| DNA Labs UAE \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE